Trastuzumab Derustecan in HER2-low Metastatic Breast Cancer

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

• IRAS ID

  1003048

• Contact name

  Richard Baird

• Contact email

  richard.baird@medschl.cam.ac.uk

• Sponsor organisation

  AstraZeneca UK Limited

• Eudract number

  2019-004493-26

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  20/LO/1099

• Date of REC Opinion

  25 Nov 2020

• REC opinion

  Further Information Favourable Opinion